AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Halozyme Therapeutics, Inc.
Video analysis: HALO
All videosNo video analysis for this stock yet. Request one from our team.
News: HALO
Record Revenue Growth Boosts Halozyme Shares
Institutions have pushed Halozyme Therapeutics, Inc. (HALO) shares up 769% since March 2014.
Which Is the Better Healthcare ETF: Fidelity's Low-Cost FHLC or First Trust's High-Conviction FBT?
One fund offers broad sector exposure at 0.08% cost; the other concentrates on 30 biotech stocks with higher volatility but stronger recent returns.
Halozyme Therapeutics, Inc. (HALO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
Halozyme Therapeutics, Inc. (HALO) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
4 High-Growth GARP Stocks With Discounted PEG Ratios for 2026
Four GARP stocks combine discounted PEG ratios with strong growth prospects, offering investors value and potential in 2026.
Halozyme to Participate at Upcoming Investor Conferences
SAN DIEGO, Sept. 2, 2026 /PRNewswire/ -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) ("Halozyme") today announced that Dr. Helen Torley, President and Chief Executive Officer, and Darren Snellgrove, Chief Financial Officer, are scheduled to participate and host investor meetings at the following investor conferences.
Halozyme: The Market May Be Underpricing The Second Growth Wave
Halozyme Therapeutics is evolving into a diversified, high-margin royalty platform, reducing reliance on single assets like DARZALEX SC. HALO delivered 48% YoY revenue growth in 2Q26, with royalty revenue up 50% and EBITDA margins reaching 68%; full-year guidance was raised across all key metrics. Royalty streams are broadening across mature and new products, with sequential growth from recent launches and a robust pipeline targeting launches from 2029 onward.
Is Halozyme Therapeutics (HALO) a Solid Growth Stock? 3 Reasons to Think "Yes"
Halozyme Therapeutics (HALO) possesses solid growth attributes, which could help it handily outperform the market.
Canada Pension Plan Investment Board Purchases Shares of 132,600 Halozyme Therapeutics, Inc. $HALO
Canada Pension Plan Investment Board acquired a new position in shares of Halozyme Therapeutics, Inc. (NASDAQ: HALO) during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 132,600 shares of the biopharmaceutical company's stock, valued at approximately $10,379,000. Canada Pension Plan Investment
